Sign Out
When used consecutively, the possibility of serious radio sensitization calls for an interval of at least 4-weeks between gemcitabine chemotherapy and radiotherapy. This interval can be shorter if required by the patient condition. Increased toxicity has been reported when infusion time is prolonged and recommended interval between doses is reduced. Like other cytotoxic, gemcitabine can induce bone-marrow suppression, resulting in anaemia, leukopenia and thrombocytopenia. This thrombocytopenia is often severe and platelet transfusions can sometimes be necessary. However, the myelosuppression is of short duration and does not usually require dosage reduction, and rarely requires the discontinuation of treatment.
Hypersensitivity: Anaphylactic reaction has been rarely reported.
